Identifying new targets for reducing colorectal and endometrial cancer risk
Official title: Discovering New Targets for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction
Run by Weill Medical College of Cornell University · NCT06096688 · Data updated 2026-11-12
This study is trying to find new ways to lower the risk of colorectal and endometrial cancer by looking at genetic information and family histories from patients who have been screened for these cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1120 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | May 29, 2019 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | August 3, 2026 |
| Trial ID | NCT06096688 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with hereditary cancer syndromes, those undergoing endoscopic procedures for average-risk screening, and patients diagnosed with colorectal or endometrial cancer seeking treatment.
✕Probably not a fit
Patients without a hereditary cancer syndrome or those not undergoing relevant screening procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and store data, tissue samples, and personal and family histories from patients screened for colorectal and endometrial cancer at NYP and Weill Cornell Medicine. The study focuses on understanding the heritable components of these cancers by analyzing genomic and epigenetic profiles of patients with hereditary cancer syndromes and those with sporadic cases. Researchers will investigate gene expression and protein profiles in various tissues to discover novel mechanisms of carcinogenesis and identify potential targets for therapy and prevention.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for cancer risk reduction and targeted therapies for patients with hereditary cancer syndromes.
How similar studies have gone: Other studies have shown success in identifying genetic predispositions and mechanisms in cancer, making this approach promising yet still novel in its specific focus on colorectal and endometrial cancers.
Who can join: the full rules
Show full inclusion / exclusion criteria
The following eligibility criteria must be met as follows: 1. Age ≥ 18 years old. 2. One of the following must be met: 1. Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and/or clinical criteria to undergo an endoscopy procedure (esophagoduodenoscopy and/or colonoscopy/flexible sigmoidoscopy), or endometrial screening procedure (transvaginal ultrasound and/or hysteroscopy and/or endometrial biopsy), OR 2. Individuals coming to Weill-Cornell Medicine/NYPH to undergo an endoscopy procedure, transvaginal ultrasound, or hysteroscopy for average-risk (population-based) recommendation OR 3. Individuals diagnosed with colorectal cancer or endometrial cancer coming to Weill- Cornell Medicine/NYPH for surgical treatment OR 4. Individuals coming to Weill-Cornell Medicine/NYPH for care such as, but not limited to, diagnostic testing, clinic and/or treatment visit. 3. Willingness and ability to sign informed consent. 4. Ability to read/understand English, Spanish, and/or simplified Chinese.
Where it's running
-
NYP/Weill Cornell Medicine
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Julie M Blander, PhD — Weill Medical College of Cornell University
- Study coordinator: Julie M Blander, PhD
- Email: jub2031@med.cornell.edu
- Phone: 646-962-6741
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
-
First-in-human test of HH160 in people with advanced solid tumors
HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Predicting Immunotherapy Response from Live Tumor Biopsies
This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.
-
STRO-004 treatment in adults with recurrent or metastatic solid tumors
This study will test whether STRO-004, alone and with pembrolizumab, is safe and can shrink tumors in adults with several types of metastatic cancers that often express Tissue Factor.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.